Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Page 20 of 84« First...10...1819202122...304050...Last »

DNA Brain Injection Could Help Parkinson’s

A biotech company called Voyager Therapeutics now thinks it can extend the effects of L-Dopa by using a surprising approach: gene therapy.

Read More »

Cinven to acquire Bioclinica

International private equity firm Cinven announced a deal to acquire Bioclinica, a global provider of clinical trial services and technology to contract research organizations and pharmaceutical companies, from Water Street Healthcare Partners and JLL Partners.

Read More »

DS Biopharma Spins Out New Company Focused on Fibrotic Conditions and Pulmonary Disorders

Privately held DS Biopharma is spinning out a new company called Afimmune that is focused solely on fibrotic conditions such as NASH and pulmonary disorders including COPD and IPF.

Read More »

Auris’ tinnitus drug misses main study goals

Auris Medical Holding AG said its experimental drug for acute inner ear tinnitus missed the main goals of a late-stage study.

Read More »

OncoGenex prostate cancer drug study fails

OncoGenex is exploring strategic alternatives after its experimental drug failed to show survival benefit in a late-stage study for advanced prostate cancer.

Read More »

Vertex Dumps Phase III Cystic Fibrosis Study

Vertex Pharmaceuticals Inc. announced it terminated clinical development of one late-stage trial studying the combination of its investigational cystic fibrosis compound VX-661 with the approved cystic fibrosis drug Kalydeco.

Read More »

Pain drugs in pregnancy tied to behavior issues

Women who take the pain reliever acetaminophen during pregnancy may be more likely to have children with behavior problems than those who do not.

Read More »

Briefly standing reduces blood sugar across day

For obese people who sit for most of the day, replacing some sitting time with standing, slow walking or slow cycling reduces average blood sugar across the day.

Read More »

U.S. government shifts $81 million to Zika research

The HHS has shifted $81 million in funds from other projects to continue work on developing vaccines to fight Zika in the absence of any funding from U.S. lawmakers.

Read More »

Paralysis partly reversed using brain-machine interface training

Paraplegic patients recovered partial limb control and feeling after using brain-machine interface technologies.

Read More »

AstraZeneca invests more on mRNA drugs

AstraZeneca has invested another $140 million in Moderna Therapeutics’ drugs based on a molecule known as messenger RNA.

Read More »

Lilly breast cancer drug stumbles; trial continues

Eli Lilly’s late-stage trial of its experimental breast cancer combination drug will continue even though it failed to meet its interim effectiveness goal.

Read More »

FDA moves Eisai Alzheimer’s drug to Phase III

Japan’s Eisai Co. said the U.S. FDA had confirmed that there was sufficient data to start Phase III studies of a drug it is co-developing to treat early Alzheimer’s disease.

Read More »

AstraZeneca’s selumetinib fails lung cancer study

AstraZeneca’s cancer drug pipeline suffered a setback when the experimental drug selumetinib failed to meet its goal in a late-stage trial for lung cancer.

Read More »

Mesoblast cell treatment shows promise in RA: study

Mesoblast Ltd. said its experimental stem-cell treatment led to significant improvements of symptoms and disease activity in patients whose rheumatoid arthritis had stopped being helped by widely used biotech medicines.

Read More »

Compound found for parasitic tropical diseases

Scientists have found a single class of drugs that can kill the parasites responsible for three tropical diseases that affect millions in Africa, Asia and Latin America.

Read More »

MEI Pharma and Helsinn Reach Cancer Deal

Helsinn Group and MEI Pharma inked an exclusive licensing, development and commercialization deal to develop and market Pracinostat to treat AML.

Read More »

Novartis asthma pill shows promise in small trial

The first new asthma pill in decades has produced promising results in a small study, potentially paving the way for another treatment option by the end of the decade.

Read More »

Bristol-Myers’ Opdivo fails lung cancer trial

Bristol-Myers Squibb’s blockbuster Opdivo failed to slow progression of symptoms in previously untreated patients with advanced lung cancer in a late-stage study.

Read More »

Concomitant medications in clinical trials: Why the stakes are high

Almost every reported concomitant medication has a reason – and many, if not all of these reasons should be reported as adverse events.

Read More »

Page 20 of 84« First...10...1819202122...304050...Last »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

February 2018 Focus: Top 10 Pipelines, Focused Value in Pharma, Agenda 2018 and MAHF!


Ad Right Bottom

Main Navigation